Europe has authorized a novel treatment for acne, offering a potential breakthrough after four decades of limited advancements.Winlevi, a topical cream designed to regulate sebum production, received the green light from European regulators and is already available in the United States and the United Kingdom.
Acne, often associated with adolescence, impacts a significant portion of adults – approximately 25% – making effective treatments crucial for millions. Winlevi’s approval marks a significant step forward in addressing this widespread dermatological condition.
Approved for use in patients aged 12 and older, Winlevi utilizes clascoterone, a molecule that inhibits the growth of hormones driving sebum production. Unlike oral medications like Roaccutane, Winlevi is applied topically as a cream twice daily to the face.
A Long-Awaited Advance
Dermatologists have anticipated a treatment like winlevi for 40 years. “It was quite expected because it is true that we have at our disposal a certain number of creams or gels, but it is true that for many years, we had no significant advance,” explains Professor Nicolas Dupin, head of the dermatology department and member of the French Society of Dermatology.
While Winlevi is now approved for use in Europe, its availability in France hinges on a decision from the High Authority for Health regarding marketing authorization, anticipated next year. The final price and reimbursement details will be determined at a later date.
